These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib? Faivre S; de Gramont A; Raymond E Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978 [No Abstract] [Full Text] [Related]
5. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Edeline J; Crouzet L; Campillo-Gimenez B; Rolland Y; Pracht M; Guillygomarc'h A; Boudjema K; Lenoir L; Adhoute X; Rohou T; Boucher E; Clément B; Blanc JF; Garin E Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):635-43. PubMed ID: 26455499 [TBL] [Abstract][Full Text] [Related]
6. Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report. Chen KH; Weng MT; Chou YH; Lu YF; Hsieh CH Medicine (Baltimore); 2016 Mar; 95(11):e3133. PubMed ID: 26986168 [TBL] [Abstract][Full Text] [Related]
7. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma. İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964 [No Abstract] [Full Text] [Related]
8. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249 [TBL] [Abstract][Full Text] [Related]
9. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808 [TBL] [Abstract][Full Text] [Related]
10. [A case of tuberculosis that occurred during treatment of hepatocellular carcinoma with sorafenib]. Kobayashi Y; Emura M; Nakamura T; Cho T; Seto R; Nomura N; Nomizo T; Igarashi S Kekkaku; 2013 Sep; 88(9):671-5. PubMed ID: 24298694 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. Edeline J; Crouzet L; Le Sourd S; Larible C; Brunot A; Le Roy F; Cattenoz C; Latournerie M; Gédouin D; Guillygomarc'h A; Boucher E Cancer Chemother Pharmacol; 2015 Jan; 75(1):215-9. PubMed ID: 25477009 [TBL] [Abstract][Full Text] [Related]
12. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma. Park H; Han SH; Kang H; Park K Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299 [No Abstract] [Full Text] [Related]
14. Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Brade AM; Ng S; Brierley J; Kim J; Dinniwell R; Ringash J; Wong RR; Cho C; Knox J; Dawson LA Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):580-7. PubMed ID: 26867886 [TBL] [Abstract][Full Text] [Related]
15. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278 [TBL] [Abstract][Full Text] [Related]
16. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. Cho JY; Paik YH; Park HC; Yu JI; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC Liver Int; 2014 May; 34(5):795-801. PubMed ID: 24350564 [TBL] [Abstract][Full Text] [Related]